A5114994811- Health Systems, Economic Evaluations, Quality of Life
- Psoriasis: Treatment and Pathogenesis
- Inflammatory Bowel Disease
- Pharmaceutical studies and practices
- Biosimilars and Bioanalytical Methods
- Complementary and Alternative Medicine Studies
- Rheumatoid Arthritis Research and Therapies
- Statistical Methods in Clinical Trials
- Antifungal resistance and susceptibility
- Hepatitis C virus research
- Synthesis and biological activity
- Pharmaceutical Economics and Policy
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
Bristol-Myers Squibb (United States)
2023-2025
Bristol-Myers Squibb (Germany)
2022-2023
Pharmerit (United States)
2019
Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared long-term efficacies of deucravacitinib and adalimumab using results from extension (LTE) trials. Open-label LTE trials were identified for indirect treatment comparison (deucravacitinib: POETYK PSO-LTE [NCT04036435]; adalimumab: REVEAL [NCT00195676]). To ensure design comparability, patients initially randomized...
Background Understanding the economic value of deucravacitinib and apremilast could assist treatment decision-making for patients with moderate to severe plaque psoriasis.
Evidence supports the clinical benefits of early aggressive biologic treatment in patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but cost-effectiveness intervention originator biologics such as tumor necrosis factor inhibitors (TNFis) or their biosimilars has not been well studied. We developed a Markov model estimate lifetime costs and utilities for established RA do respond methotrexate...
Objective: Persistence to therapy treat rheumatoid arthritis (RA) is an indirect measure of tolerability and effectiveness in the real-world setting. Previous clinical trials suggested that seropositive RA patients may particularly benefit from abatacept. The risk non-persistence initiating abatacept, tumor necrosis factor inhibitors (TNFi), janus kinase (JAKi) as first-line biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) was examined.Methods: We performed a...
This real-world study investigated the impact of patient-reported disease burden and health-related quality life (HRQoL) on switching from systemic nonbiologic to biologic therapy in patients with plaque psoriasis.
Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate severe plaque psoriasis the POETYK PSO-1 and PSO-2 clinical trials. In study reported here, we aimed determine overall 52-week cumulative benefit of treatment initiated deucravacitinib versus compare initiating staying on continuing or switching at week 24 treatment. This post hoc analysis data (ClinicalTrials.gov identifier: NCT03624127) determined 6 mg once daily 30 twice adults psoriasis. Patients...
Introduction: Better understanding of the relationship between quality life and treatment patterns in psoriasis may help guide therapeutic algorithms. This study evaluated association patient-reported disease burden switching from nonbiologic to biologic therapy patients with plaque enrolled CorEvitas Psoriasis Registry.
 Methods: cross-sectional included biologic-naive aged ≥18 years who had used systemic 28–365 days prior their registry enrollment April 2015 August 2022. A switch was...
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the US for treatment of adults with moderate to severe plaque psoriasis (PsO). A previous indirect study showed comparable efficacy between deucravacitinib and first-generation biologics at week 52. The objective this was compare long-term that adalimumab based on extension (LTE) trials, after adjusting differences patient characteristics baseline. 
 Methods: Open-label LTE...
Despite demonstration of bioequivalence generics to brands and the potential for reduced costs, some patients switch back from a generic brand. A prior retrospective analysis suggested that this switchback rate may be lower among had initially switched authorized (AG), often both produced marketed by brand company, compared those another generic.Explore switching patterns brands, AGs, generics, rates, impact switchbacks on healthcare costs.An Pharmetrics Plus™ database (2007-2019), United...
N/A